Sugi Predict

Sugi Predict / Compounds / SCHEMBL1124591

SCHEMBL1124591

SCHEMBL1124591

COC(=O)CCc1cccc(O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SPR P35270 1/20 0.57
▸ GABRA1 P14867 1/20 0.53
▸ GABRG2 P18507 1/20 0.53
▸ GABRB3 P28472 1/20 0.53
▸ GABRA3 P34903 1/20 0.53
▸ GABRA2 P47869 1/20 0.53
▸ GABRB2 P47870 1/20 0.53
▸ HDAC6 Q9UBN7 1/20 0.53
▸ SIRT2 Q8IXJ6 1/20 0.52
▸ CHRM2 P08172 2/20 0.50
▸ CHRM1 P11229 2/20 0.50
▸ CHRM3 P20309 2/20 0.50
▸ DRD2 P14416 2/20 0.50
▸ DRD1 P21728 2/20 0.50
▸ TAAR1 Q96RJ0 1/20 0.50
▸ HSP90AB1 P08238 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ TYR P14679 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30655576 1.00 SPR (0.57) SPRGABRA1GABRG2GABRB3GABRA3
SCHEMBL28151357 0.90 HDAC6 (0.57) SPRGABRA1GABRG2GABRB3GABRA3
SCHEMBL27973686 0.89 SPR (0.54) SPRGABRA1GABRG2GABRB3GABRA3
SCHEMBL22673499 0.87 HDAC6 (0.67) SPRGABRA1GABRG2GABRB3GABRA3
SCHEMBL21114392 0.86 DRD2 (0.53) SPRGABRA1GABRG2GABRB3GABRA3
SCHEMBL2745464 0.83 CYP4F2 (0.57) SPRHDAC6CHRM2CHRM1CHRM3
SCHEMBL12646452 0.83 HCAR2 (0.56) —
SCHEMBL28655132 0.83 SLC7A5 (0.57) SIRT2HSP90AB1ALDH1A1KDM4ELMNA
SCHEMBL12255149 0.83 SIRT2 (0.52) HDAC6SIRT2ALDH1A1KDM4ELMNA
SCHEMBL1410879 0.83 SIRT2 (0.52) SIRT2ALDH1A1KDM4ELMNACYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117142955-A Method for catalyzing carbonylation esterification reaction by cobalt promoted by molybdenum disulfide 中国科学院兰州化学物理研究所 2023-12-01 — — CN claimed
CN-116730836-A Method for catalyzing carbonylation esterification reaction by cobalt salt activated by synthesis gas 中国科学院兰州化学物理研究所 2023-09-12 — — CN claimed
CN-111197085-A Intestinal flora biomarker related to autism and application thereof 中国科学院北京基因组研究所 2020-05-26 — — CN claimed
EP-2916837-A1 PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-09-16 — — EP claimed
WO-2014074421-A1 PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-05-15 — — WO claimed
EP-4720076-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. Lundbeck A/S (DK) 2026-04-08 — — EP disclosed
US-12590106-B2 Spiromacrocyclic orexin 2 receptor agonists H. LUNDBECK A/S (DK) 2026-03-31 — — US disclosed
US-20250263422-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2025-08-21 — — US disclosed
US-20250188023-A1 BENZENE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2025-06-12 — — US disclosed
WO-2025087431-A1 PAN-KRAS INHIBITOR AND USE THEREOF IN MEDICINES 贝达药业股份有限公司 2025-05-01 — — WO disclosed
US-12258308-B2 Benzene derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2025-03-25 — — US disclosed
US-20240425521-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2024-12-26 — — US disclosed
CN-1028173-C Process for preparing oxazole derivatives BRISTOL MYERS SQUIBB CO (US) 1995-04-12 — — CN disclosed
CN-1101041-A Process for preparing oxazole derivatives BRISTOL MYERS SQUIBB CO (US) 1995-04-05 — — CN disclosed
CN-1101042-A Process for preparing oxazole derivatives BRISTOL MYERS SQUIBB CO (US) 1995-04-05 — — CN disclosed
CN-1101043-A Process for preparing oxazole derivatives BRISTOL MYERS SQUIBB CO (US) 1995-04-05 — — CN disclosed
US-5262540-A FOR INHIBITION OF BLOOD PLATELET AGGREGATION IN MAMMALS BRISTOL-MYERS SQUIBB COMPANY (US) 1993-11-16 — — US disclosed
CN-1052667-A OXAZOLE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 1991-07-03 — — CN disclosed
EP-0434034-A1 Oxazole derivatives Bristol-Myers Squibb Company (US) 1991-06-26 — — EP disclosed
US-4761420-A CARDIOVASCULAR DISORDERS LABORATOIRES SYNTEX S.A. (FR) 1988-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258308-B2 Benzene derivative PMP22, TMBIM6, MYT1 SPR 4648/4885GABRA1 428/4885GABRG2 420/4885
US-20250188023-A1 BENZENE DERIVATIVE PMP22, TMBIM6, MYT1 SPR 4678/4885GABRA1 423/4885GABRG2 422/4885
US-12590106-B2 Spiromacrocyclic orexin 2 receptor agonists HCRTR2, HCRTR1, OXER1 SPR 2960/4885GABRA1 393/4885GABRG2 985/4885
US-20250263422-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS HCRTR2, HCRTR1, CRHR2 SPR 2552/4885GABRA1 215/4885GABRG2 243/4885
US-20240425521-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS HCRTR2, HCRTR1, CRHR2 SPR 2552/4885GABRA1 215/4885GABRG2 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.